INNOVATE Corp. (VATE)
| Market Cap | 70.60M |
| Revenue (ttm) | 1.10B |
| Net Income (ttm) | -75.20M |
| Shares Out | 13.66M |
| EPS (ttm) | -5.73 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,508 |
| Open | 5.12 |
| Previous Close | 5.05 |
| Day's Range | 5.12 - 5.24 |
| 52-Week Range | 4.05 - 13.79 |
| Beta | 1.58 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 12, 2025 |
About VATE
INNOVATE Corp., through its subsidiaries, operates in infrastructure, life sciences, and spectrum areas in the United States. The Infrastructure segment provides industrial construction, structural steel, and facility maintenance services, such as fabrication and erection of structural steel and heavy steel plate services, and large-diameter water pipes and water storage tanks; fabrication of trusses and girders; and 3-D building information modeling and detailing for commercial, industrial, and infrastructure construction projects, such as bui... [Read more]
Financial Performance
In 2024, INNOVATE's revenue was $1.11 billion, a decrease of -22.20% compared to the previous year's $1.42 billion. Losses were -$35.80 million, -4.79% less than in 2023.
Financial StatementsNews
INNOVATE Corp. (VATE) Q3 2025 Earnings Call Transcript
INNOVATE Corp. ( VATE) Q3 2025 Earnings Call November 12, 2025 4:30 PM EST Company Participants Neel Sikka Paul Voigt - Interim Chief Executive Officer Michael Sena - CFO, Treasurer & Corporate Secre...
INNOVATE Corp. Announces Third Quarter 2025 Results
- Infrastructure: DBM Global delivers robust revenue growth, reinforcing market leadership - - Life Sciences: MediBeacon received regulatory approval to sell the Transdermal GFR System in China - - Sp...
INNOVATE Corp. to Report Third Quarter 2025 Results on November 12th
NEW YORK, Oct. 22, 2025 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) announced today that it will release its financial results for the third quarter 2025 on Wednesday...
MediBeacon receives regulatory approval to sell the Transdermal GFR System in China
NEW YORK, Oct. 21, 2025 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) announced today that MediBeacon Inc., a medical technology company specializing in the advancement...
INNOVATE's Portfolio Company DBM Global to Pay Cash Dividend
NEW YORK, Oct. 16, 2025 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) announced today that DBM Global Inc. (“DBMG”), a family of companies providing fully integrated st...
INNOVATE's Portfolio Company, R2, has Explosive Growth and Global Reach with Glacial® Skin Continuing to Redefine Aesthetic Innovation
NEW YORK, Sept. 09, 2025 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) today announced that R2 Technologies, Inc. (“R2”), the innovators behind the breakthrough Glacial...
INNOVATE Corp. (VATE) Q2 2025 Earnings Call Transcript
INNOVATE Corp. (NYSE:VATE) Q2 2025 Earnings Conference Call August 5, 2025 4:30 PM ET Company Participants Michael J. Sena - CFO, Treasurer & Corporate Secretary Neel Sikka - Corporate Participant Pa...
INNOVATE Corp. Announces Second Quarter 2025 Results
- Infrastructure: Improved financial flexibility with recent refinancing transactions - - Life Sciences: R2 continuing to see significant year over year growth in system unit sales - - Spectrum: Launc...
INNOVATE Closes Indebtedness Refinancing Transactions
NEW YORK, Aug. 04, 2025 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) today announced that it has closed a series of previously announced indebtedness refinancing trans...
INNOVATE Announces Early Results of Exchange Offer of Senior Secured Notes and Solicitation of Consents and Extends Availability of Total Early Exchange Consideration
NEW YORK, July 31, 2025 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) today announced the early participation results as of 5:00 p.m., New York City time, on July 30, 2...
INNOVATE Corp. to Report Second Quarter 2025 Results on August 5th
NEW YORK, July 17, 2025 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) announced today that it will release its financial results for the second quarter 2025 on Tuesday,...
INNOVATE Launches Indebtedness Refinancing Transactions
$48.7 million privately negotiated convertible notes exchanges.$330 million exchange offer of senior secured notes and solicitation of consentsAgreement in principle to extend revolving credit agreeme...
DBM Global Enters Into an Amended and Restated Credit Agreement
NEW YORK, May 20, 2025 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) announced today that DBM Global Inc. (“DBMG”), has entered into an amended and restated credit agre...
INNOVATE Corp. (VATE) Q1 2025 Earnings Call Transcript
INNOVATE Corp. (NYSE:VATE) Q1 2025 Earnings Conference Call May 6, 2025 4:30 PM ET Company Participants Anthony Rozmus - Investor Relations Paul Voigt - Interim Chief Executive Officer Mike Sena - Ch...
INNOVATE Corp. Announces First Quarter 2025 Results
- Infrastructure: DBM Global first quarter revenue of $264.9 million - - Life Sciences: MediBeacon ® Transdermal GFR (“TGFR”) System Received FDA Approval to Assess Kidney Function - - Spectrum: Expec...
INNOVATE Corp. to Report First Quarter 2025 Results on May 6th
NEW YORK, April 16, 2025 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) announced today that it will release its financial results for the first quarter 2025 on Tuesday,...
INNOVATE Corp. (VATE) Q4 2024 Earnings Call Transcript
INNOVATE Corp. (NYSE:VATE) Q4 2024 Earnings Conference Call March 31, 2025 4:30 PM ET Company Participants Neel Sikka - Investor Relations Paul Voigt - Interim Chief Executive Officer Mike Sena - Chi...
INNOVATE Corp. Announces Fourth Quarter and Full Year 2024 Results
- Infrastructure: DBM Global fourth quarter revenue of $225.7 million - - Life Sciences: MediBeacon ® Transdermal GFR (“TGFR”) system received FDA approval to assess kidney function - - Spectrum: Broa...
INNOVATE Corp. to Report Fourth Quarter and Full Year 2024 Results on March 31st
NEW YORK, Feb. 27, 2025 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) announced today that it will release its financial results for the fourth quarter and full year 20...
MediBeacon® Transdermal GFR System receives device approval in China
Transdermal GFR System (TGFR) is a first-in-kind product for point of care assessment of kidney function in patients with normal or impaired renal function. The Clinical Kidney Journal in February pub...
MediBeacon® Transdermal GFR System Receives FDA Approval to Assess Kidney Function
NEW YORK, Jan. 17, 2025 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) announced today that the U.S. Food and Drug Administration (FDA) has approved the MediBeacon® TGFR...
INNOVATE Corp. Portfolio Company R2 Technologies Announces Another Record-Breaking Quarter and Partnerships with Woodhouse Spas and Top Skincare Brands
NEW YORK, Nov. 20, 2024 (GLOBE NEWSWIRE) -- R2 Technologies, Inc., the world leader in CryoAesthetics® with its cutting-edge Glacial Skin systems (“R2”), a portfolio company of INNOVATE Corp. (NYSE: V...
INNOVATE Corp. (VATE) Q3 2024 Earnings Call Transcript
INNOVATE Corp. (VATE) Q3 2024 Earnings Call Transcript
INNOVATE Corp. Announces Third Quarter 2024 Results
- Infrastructure: DBM Global third quarter revenue of $232.8 million - - Life Sciences: R2 reports record worldwide system unit sales growth in the third quarter - - Spectrum: Broadcasting's delivered...
INNOVATE Corp. to Report Third Quarter 2024 Results on November 6th
NEW YORK, Oct. 16, 2024 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) announced today that it will release its financial results for the third quarter 2024 on Wednesday...